LDLR

(redirected from low-density lipoprotein receptor)

LDLR

A gene on chromosome 19p13.2 that encodes a cell surface protein involved in receptor-mediated endocytosis of low-density lipoprotein (LDL), the major cholesterol-carrying lipoprotein of plasma, which it transports into cells by endocytosis. Internalisation of the receptor-ligand complex requires clustering into clathrin-coated pits.
References in periodicals archive ?
as a novel locus for autosomal dominant hypercholesterolemia, with a phenotype clinically similar to familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene (2).
2005) [14], their study also shows that tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independent of low-density lipoprotein receptor gene mutation.
PCSK9 disrupts the activity of a key molecule called the low-density lipoprotein receptor, or LDLR, which is made and secreted in the liver.
Colesevelam significantly increased hepatic gene expression for scavenger receptor type BI, apolipoprotein A1, LCAT, cholesterol ester transfer protein, cholesterol 7-[alpha]-hydroxylase (CYP7A1), low-density lipoprotein receptor, and liver X receptor (LXR).
Contrary to the accepted hypothesis positing downregulation of low-density lipoprotein receptor (LDLR) in humans, expression of the human APOE4 isoform combined with increased LDLR was harmful in genetically modified mice when red a high-fat Western diet, predicting important interactions between genotype/phenotype and exposure.
However, two of the lipoprotein receptors, the very low-density lipoprotein receptor (VLDLR) and Apolipoprotein E receptor 2 (ApoER2), are present in the brain.
Secreted proprotein convertase subtilisin/kexin-type 9 downregulates low-density lipoprotein receptor through receptor-mediated endocytosis.
Therefore, the Illinois team suspects that the proteins are influencing a low-density lipoprotein receptor in the liver that also affects cholesterol metabolism, Larson says.
Angiochem utilizes its proprietary platform for Engineered Peptide Compounds (EPiC) to discover and develop drugs that cross the blood-brain barrier through Low-Density Lipoprotein Receptor Related Protein-1 (LRP-1) targeting.
Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor.
Secreted proprotein convertase subtilisin/kexin-type 9 reduces low-density lipoprotein receptor through receptor-mediated endocytosis.

Full browser ?